SET/TAF-I anticorps (N-Term)

N° du produit ABIN374103

Détail du produit anti-SET/TAF-I anticorps

Antigène: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Épitope: N-Term

Reactivité: Humain

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp SET/TAF-I est non-conjugé

Application: Western Blotting (WB)

Séquence: SAPAAKVSKK ELNS-C

Specificité: This antibody detects SET / I2PP2A at N-term.

Réactivité croisée (Details): Species reactivity (expected):Bovine (Cow)Species reactivity (tested):Human.

Purification: Ammonium Sulphate Precipitation followed by antigen Affinity Chromatography using the immunizing peptide

Immunogène: Peptide from the N Terminus of the protein sequence according to NP_003002.2

Information d'application

Indications d'application: Peptide ELISA: Limit Dilution 1/1000. Western blot: 1-3 μg/mL. Approx 20-25 kDa and 45 kDa bands seen in Human Kidney

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Tris saline, pH 7.3 containing 0.02 % Sodium Azide as preservative and 0.5 % BSA as stabilizer.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur SET/TAF-I

Antigène: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Autre désignation: SET / I2PP2A (SET Produits)

Synonymes: anticorps 2PP2A, anticorps I2PP2A, anticorps IGAAD, anticorps IPP2A2, anticorps PHAPII, anticorps TAF-I, anticorps TAF-IBETA, anticorps 2610030F17Rik, anticorps 5730420M11Rik, anticorps AA407739, anticorps I-2PP2A, anticorps StF-IT-1, anticorps 2pp2a, anticorps i2pp2a, anticorps igaad, anticorps ipp2a2, anticorps phapii, anticorps set, anticorps set-a, anticorps set-b, anticorps taf-ibeta, anticorps wu:fb30g11, anticorps wu:fd16c08, anticorps SET nuclear proto-oncogene, anticorps SET nuclear oncogene, anticorps SET translocation, anticorps SET nuclear proto-oncogene L homeolog, anticorps SET nuclear proto-oncogene b, anticorps SET, anticorps Set, anticorps LOC403555, anticorps set.L, anticorps setb

Sujet: SET belongs to a family of multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone binding. There are two named isoforms produced by alternative splicing: Isoform 1 and Isoform 2. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins, however, isoform 2 specific activity is higher. Isoform 1 and isoform 2 interact directly with each other and with ANP32A within the tripartite INHAT (inhibitor of acetyltransferases) complex. A chromosomal aberration involving SET is found in some cases of acute undifferentiated leukemia (AUL). Translocation t(6,9)(q21,q34.1) with NUP214/CAN.Synonyms: I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I

ID gène: 6418

NCBI Accession: NP_003002

UniProt: H0UI37

Pathways: Apoptose